Skip to main content
. 2006 Feb 28;94(9):1217–1220. doi: 10.1038/sj.bjc.6603025

Table 1. Activity of anti-VEGF agents in metastatic renal cell carcinoma trials.

  No ORR (%) CR+PR+SD (%) PFS /TTP (months)
Sunitinib (Phase II)
 Trial 1 63 40 67 8.2 (pooled analysis both studies)
 Trial 2 105 44 67  
         
Sorafenib (Phase III) 451 10 74 5.5
AG-013736 (Phase II) 52 46 86 Not reached
Bevacizumab (Phase II) 39 10   4.8